AU2008302201A1 - Soluble dosage forms containing cephem derivatives suitable for parenteral administration - Google Patents

Soluble dosage forms containing cephem derivatives suitable for parenteral administration Download PDF

Info

Publication number
AU2008302201A1
AU2008302201A1 AU2008302201A AU2008302201A AU2008302201A1 AU 2008302201 A1 AU2008302201 A1 AU 2008302201A1 AU 2008302201 A AU2008302201 A AU 2008302201A AU 2008302201 A AU2008302201 A AU 2008302201A AU 2008302201 A1 AU2008302201 A1 AU 2008302201A1
Authority
AU
Australia
Prior art keywords
dosage form
ceftaroline
mean
acid
fosamil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008302201A
Other languages
English (en)
Inventor
Mahendra Dedhiya
Yigong Ge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008302201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2008302201A1 publication Critical patent/AU2008302201A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: FOREST LABORATORIES HOLDINGS LIMITED
Priority to AU2013200744A priority Critical patent/AU2013200744A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2008302201A 2007-09-21 2008-09-19 Soluble dosage forms containing cephem derivatives suitable for parenteral administration Abandoned AU2008302201A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013200744A AU2013200744A1 (en) 2007-09-21 2013-02-12 Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97419407P 2007-09-21 2007-09-21
US60/974,194 2007-09-21
PCT/US2008/076920 WO2009039324A1 (en) 2007-09-21 2008-09-19 Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013200744A Division AU2013200744A1 (en) 2007-09-21 2013-02-12 Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Publications (1)

Publication Number Publication Date
AU2008302201A1 true AU2008302201A1 (en) 2009-03-26

Family

ID=40468354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008302201A Abandoned AU2008302201A1 (en) 2007-09-21 2008-09-19 Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Country Status (11)

Country Link
US (3) US20090082326A1 (enExample)
EP (2) EP2200618A4 (enExample)
JP (1) JP2010540448A (enExample)
KR (1) KR101599560B1 (enExample)
CN (3) CN103919720A (enExample)
AU (1) AU2008302201A1 (enExample)
BR (1) BRPI0816412A2 (enExample)
CA (1) CA2700263A1 (enExample)
MX (1) MX2010003112A (enExample)
RU (1) RU2537237C2 (enExample)
WO (1) WO2009039324A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121819A1 (es) * 2009-09-21 2013-02-01 Astrazeneca Ab Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
WO2016008393A1 (zh) * 2014-07-14 2016-01-21 正大天晴药业集团股份有限公司 头孢罗膦氨基酸盐及其结晶
CN104258403B (zh) * 2014-09-28 2017-03-01 刘宗侠 一种西洛他唑组合物及其制备方法
KR20170038214A (ko) * 2015-09-30 2017-04-07 (주)아모레퍼시픽 당산 및 플라보노이드를 포함하는 항균용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028355A (en) * 1974-01-23 1977-06-07 Smithkline Corporation Cephalosporin purification process
GB8729574D0 (en) * 1987-12-18 1988-02-03 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition
JP2761005B2 (ja) * 1988-11-02 1998-06-04 エーザイ株式会社 セファロスポリン含有注射用組成物
JPH02124822A (ja) * 1988-11-02 1990-05-14 Eisai Co Ltd セファロスポリン含有注射用組成物
EP0395219B1 (en) * 1989-03-30 1998-09-30 Pfizer Inc. Cephalosporins and their homologues, process for their preparation and pharmaceutical compositions
DK0421297T3 (da) * 1989-09-30 1994-01-17 Eisai Co Ltd Injicerbare præparater indeholdende cephalosporin som lægemiddel og anvendelse deraf
JPH0840907A (ja) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤
TW473479B (en) 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
JP3586226B2 (ja) * 2000-08-10 2004-11-10 武田薬品工業株式会社 ホスホノセフェム化合物
PT1310502E (pt) * 2000-08-10 2009-07-31 Takeda Pharmaceutical Composto de fosfonocefem
TWI344847B (en) 2003-04-28 2011-07-11 Takeda Chemical Industries Ltd Composition for injection

Also Published As

Publication number Publication date
WO2009039324A1 (en) 2009-03-26
RU2537237C2 (ru) 2014-12-27
CN102935065A (zh) 2013-02-20
EP2952195A1 (en) 2015-12-09
BRPI0816412A2 (pt) 2017-05-16
JP2010540448A (ja) 2010-12-24
KR20100075942A (ko) 2010-07-05
CN103919720A (zh) 2014-07-16
CN101868240A (zh) 2010-10-20
US20120010180A1 (en) 2012-01-12
US20150196572A1 (en) 2015-07-16
US20090082326A1 (en) 2009-03-26
KR101599560B1 (ko) 2016-03-03
RU2010115268A (ru) 2011-10-27
EP2200618A4 (en) 2010-11-03
CA2700263A1 (en) 2009-03-26
MX2010003112A (es) 2010-08-11
EP2200618A1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
JP6870029B2 (ja) セフトロザン抗生物質組成物
RU2647972C2 (ru) Тетрациклиновая композиция
RU2658050C2 (ru) Парентеральные составы для введения макролидных антибиотиков
JP5841333B2 (ja) 安定化されたカリスバメートの小児用懸濁液
IL171337A (en) Pharmaceutical compositions containing piperacillin and tazobactam, uses thereof and processes for the preparation thereof
US9925196B2 (en) Ceftolozane-tazobactam pharmaceutical compositions
US20150196572A1 (en) Soluble dosage forms containing cephem derivatives suitable for parenteral administration
Aboubakr Evaluation of bioequivalence of two enrofloxacin formulations after intramuscular administration in goats
CN113015519A (zh) 利福布汀治疗方法、用途和组合物
AU2016234893A1 (en) Pharmaceutical Compositions
AU2013200744A1 (en) Soluble dosage forms containing cephem derivatives suitable for parenteral administration
AU2014268229A1 (en) Soluble dosage forms containing cephem derivatives suitable for parenteral administration
WO2026105164A1 (en) Non-aqueous liquid formulations of tetracycline antibiotics
AU2016364380A1 (en) Formulations for intravenous injection of danirixin
AU2015200599A1 (en) Ceftolozane Antibiotic Compositions
CN118697738A (zh) 药物及其用途
CN112294797A (zh) 裂环桉烷型倍半萜内酯a的药物用途
HK1230972A (en) Pharmaceutical compositions comprising radezolid
HK1230972A1 (en) Pharmaceutical compositions comprising radezolid
NZ554077A (en) Compositions containing piperacillin, tazobactam and a aminocarboxylic acid in sodium lactate diluent
JP2013543893A (ja) 薬学的組成物

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ASTRAZENECA AB

Free format text: FORMER APPLICANT(S): FOREST LABORATORIES HOLDINGS LIMITED

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted